Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Gilead Sciences, Inc (NASDAQ: GILD) closed at $114.15 down -0.54% from its previous closing price of $114.77. In other words, the price has decreased by -$0.54 from its previous closing price. On the day, 3.78 million shares were traded. GILD stock price reached its highest trading level at $115.5 during the session, while it also had its lowest trading level at $113.81.
Ratios:
For a deeper understanding of Gilead Sciences, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 21.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.12. For the most recent quarter (mrq), Quick Ratio is recorded 1.15 and its Current Ratio is at 1.32. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.13.
On August 08, 2025, Truist Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $127. Needham Upgraded its Hold to Buy on July 25, 2025, while the target price for the stock was maintained at $133.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 15 ’25 when Mercier Johanna sold 28,000 shares for $118.53 per share. The transaction valued at 3,318,927 led to the insider holds 114,168 shares of the business.
Dickinson Andrew D sold 2,500 shares of GILD for $296,325 on Aug 15 ’25. The Chief Financial Officer now owns 160,110 shares after completing the transaction at $118.53 per share. On Aug 15 ’25, another insider, ANDREW DICKINSON, who serves as the Officer of the company, bought 2,500 shares for $118.53 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GILD now has a Market Capitalization of 141638467584 and an Enterprise Value of 160442105856. As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.71, and their Forward P/E ratio for the next fiscal year is 13.24. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.85. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.92 while its Price-to-Book (P/B) ratio in mrq is 7.21. Its current Enterprise Value per Revenue stands at 5.559 whereas that against EBITDA is 11.625.
Stock Price History:
The Beta on a monthly basis for GILD is 0.38, which has changed by 0.48246753 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, GILD has reached a high of $121.83, while it has fallen to a 52-week low of $75.91. The 50-Day Moving Average of the stock is 1.36%, while the 200-Day Moving Average is calculated to be 9.65%.
Shares Statistics:
For the past three months, GILD has traded an average of 7.16M shares per day and 5731260 over the past ten days. A total of 1.24B shares are outstanding, with a floating share count of 1.24B. Insiders hold about 0.20% of the company’s shares, while institutions hold 87.97% stake in the company. Shares short for GILD as of 1753920000 were 19990775 with a Short Ratio of 2.79, compared to 1751241600 on 20991552. Therefore, it implies a Short% of Shares Outstanding of 19990775 and a Short% of Float of 1.6099999999999999.
Dividends & Splits
According to the company, the forward annual dividend rate for GILD is 3.12, from 3.12 in the trailing year. Against a Trailing Annual Dividend Yield of 0.027184805The stock’s 5-year Average Dividend Yield is 3.93. The current Payout Ratio is 805.23% for GILD, which recently paid a dividend on 2025-06-13 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 2013-01-28 when the company split stock in a 2:1 ratio.
Earnings Estimates
Gilead Sciences, Inc (GILD) is currently under the scrutiny of 19.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $2.12, with high estimates of $2.26 and low estimates of $2.0.
Analysts are recommending an EPS of between $8.35 and $7.97 for the fiscal current year, implying an average EPS of $8.09. EPS for the following year is $8.58, with 26.0 analysts recommending between $9.25 and $6.42.
Revenue Estimates
A total of 18 analysts believe the company’s revenue will be $7.39B this quarter.It ranges from a high estimate of $7.52B to a low estimate of $7.22B. As of the current estimate, Gilead Sciences, Inc’s year-ago sales were $7.54BFor the next quarter, 18 analysts are estimating revenue of $7.58B. There is a high estimate of $7.78B for the next quarter, whereas the lowest estimate is $7.47B.
A total of 24 analysts have provided revenue estimates for GILD’s current fiscal year. The highest revenue estimate was $29.21B, while the lowest revenue estimate was $28.51B, resulting in an average revenue estimate of $28.77B. In the same quarter a year ago, actual revenue was $28.75BBased on 25 analysts’ estimates, the company’s revenue will be $29.88B in the next fiscal year. The high estimate is $30.94B and the low estimate is $28.79B.
